Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
IPO Year: 2014
Exchange: NASDAQ
Website: agtc.com
| Date | Price Target | Rating | Analyst |
|---|
BTIG initiated coverage of Applied Genetic with a rating of Buy and set a new price target of $11.00
Stifel Nicolaus initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00
Stifel initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00
Stifel Nicolaus initiated coverage of Applied Genetic Technologies with a rating of Buy
H.C. Wainwright reiterated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $24.00 from $18.00 previously
Roth Capital reiterated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $35.00 from $30.00 previously